REGENXBIO reveals positive interim data from RGX-111 Phase I/II trial

Lineage Enters Into Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Lacerta Inks Deal with Lilly Subsidiary Prevail to Develop Novel AAV Capsids for CNS Disorders

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

Chiesi Global Rare Diseases' Lamzede receives US FDA approval

Ryne Biotechnology Awarded USD 4m from the California Institute for Regenerative Medicine

GenSight Biologics reports favourable one-year safety data and efficacy signals from PIONEER Phase I/II clinical trial of optogenetic treatment candidate GS030 to treat retinitis pigmentosa

Chinese regulator accepts Alpha Biopharma's Zorifertinib New Drug Application

First Cohort Dosed in Phase 1 Clinical Study of ADX-324

Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur

Myrtelle and rAAVen Therapeutics to Develop Novel Gene Therapy Vectors

CNS Pharmaceuticals to conduct investigator-initiated Phase 1b/2 trial of Berubicin

Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts

Azafaros Receives FDA's IND Clearance and Fast Track Designation for Lead Asset AZ-3102

Apnimed Completes Oversubscribed USD 79.75m Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea